Trade CytomX Therapeutics Inc - CTMX CFD

CytomX Therapeutics Inc Company profile

About CytomX Therapeutics Inc

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing a class of investigational conditionally activated therapeutics, based on its Probody technology platform, for the treatment of cancer. Its Probody technology platform is designed to enable conditional activation of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. The Company's product candidates include the conditionally activated antibody-drug conjugates (ADCs) praluzatamab ravtansine (CX2009, targeting CD166) and CX-2029, targeting CD71, and the Probody immune checkpoint inhibitors pacmilimab (CX-072, targeting PD-L1) and BMS-986249 (targeting CTLA-4). It also has two preclinical agents in investigational new drug (IND)-enabling studies - a conditionally activated ADC targeting EpCAM/Trop-1 (CX-2043) and a conditionally activated T-cell engaging bispecific antibody targeting EGFR and CD3 (CX-904).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, CytomX Therapeutics Inc revenues decreased 31% to $69.6M. Net loss increased from $32.9M to $83.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects General and administrative increase of 13% to $31.8M (expense), Research and development increase of 2% to $108.4M (expense).